Targeted therapy for pancreatic cancer aims at targeting mutated oncogenes such as KRAS [6] or its downstream effector molecules like MEK/ERK [7], receptor tyrosine kinases including EGFR and IGFR [8, 9] and other molecules that are up-regulated in the tumor and promote survival and proliferation. Here, IGF1R is linked to pancreatic neoplasm.